Therefore, our results indicated that defects in CHD4 resulted in greater platinum drug-induced toxicity in CRC cells, supposed that CRC patients who expressed low CHD4 are more suitable for platinum drug treatment. The gene discussed is CHD4; the disease is colorectal carcinoma.